-
1
-
-
0029984359
-
Combination therapy for HIV-1 infection. Overview: Preclinical and clinical analysis of antiretroviral combinations
-
Johnson VA: Combination therapy for HIV-1 infection. Overview: preclinical and clinical analysis of antiretroviral combinations. Antiviral Res 1996, 29:35-39.
-
(1996)
Antiviral Res
, vol.29
, pp. 35-39
-
-
Johnson, V.A.1
-
2
-
-
0028331215
-
Combination therapy for infection due to human immunodeficiency virus type 1
-
Caliendo AM, Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994, 18:516-524.
-
(1994)
Clin Infect Dis
, vol.18
, pp. 516-524
-
-
Caliendo, A.M.1
Hirsch, M.S.2
-
3
-
-
0029877789
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development
-
De Clercq E: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med Res Rev 1996, 16:125-157.
-
(1996)
Med Res Rev
, vol.16
, pp. 125-157
-
-
De Clercq, E.1
-
4
-
-
0029079399
-
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1- Specific inhibitors (i.e., TSAO derivatives)
-
Balzarini J, Perez-Perez MJ, Velazquez S, et al.: Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1- specific inhibitors (i.e., TSAO derivatives). Proc Natl Acad Sci USA 1995, 92:5470-5474.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 5470-5474
-
-
Balzarini, J.1
Perez-Perez, M.J.2
Velazquez, S.3
-
5
-
-
0028837503
-
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease
-
Fischl MA, Stanley K, Collier AC, et al.: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995, 122:24-32.
-
(1995)
Ann Intern Med
, vol.122
, pp. 24-32
-
-
Fischl, M.A.1
Stanley, K.2
Collier, A.C.3
-
6
-
-
10144244674
-
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
-
Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
-
(1996)
N Engl J Med
, vol.335
, pp. 1081-1090
-
-
Hammer, S.M.1
Katzenstein, D.A.2
Hughes, M.D.3
-
7
-
-
9444290697
-
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
-
Schooley RT, Ramirez-Ronda C, Lange JMA, et al.: Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996, 173:1354-1366.
-
(1996)
J Infect Dis
, vol.173
, pp. 1354-1366
-
-
Schooley, R.T.1
Ramirez-Ronda, C.2
Lange, J.M.A.3
-
8
-
-
8044227182
-
Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect
-
Vancouver, July [abstract MoB290]
-
Phillips AN, Fron J, Bartlett J, Hill AM, The North American Lamivudine HIV Working Group: Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB290].
-
(1996)
XI International Conference on AIDS
-
-
Phillips, A.N.1
Fron, J.2
Bartlett, J.3
Hill, A.M.4
-
9
-
-
0029563673
-
Treatment with lamivudine, zidovudine, or both in positive patients with 200 to 500 CD4+ clls per cubic millimiter
-
Eron JJ, Benot SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in positive patients with 200 to 500 CD4+ clls per cubic millimiter. N Engl J Med 1995, 333:1662-1669.
-
(1995)
N Engl J Med
, vol.333
, pp. 1662-1669
-
-
Eron, J.J.1
Benot, S.L.2
Jemsek, J.3
-
10
-
-
8044231931
-
The Interim safety results and pharmacokinetics of a combination of R89439 and zidovudine therapy in HIV-infection
-
Yokohama. August [abstract PB0252]
-
Colebunders R, Vandenbruaene M, Delescluse J. et al.: The Interim safety results and pharmacokinetics of a combination of R89439 and zidovudine therapy in HIV-infection. X International Conference on AIDS. Yokohama. August 1994 [abstract PB0252].
-
(1994)
X International Conference on AIDS
-
-
Colebunders, R.1
Vandenbruaene, M.2
Delescluse, J.3
-
11
-
-
9244247314
-
Randomized double-blind trial of loviride (R89439) (L), zidovudine (Z) and the combination in HIV-1 infected patients
-
Washington, DC, January-February [abstract LB6A]
-
Youle M, Davies S, Andries K, et al.: Randomized double-blind trial of loviride (R89439) (L), zidovudine (Z) and the combination in HIV-1 infected patients. Second National Conference on Human Retroviruses and Related Infection. Washington, DC, January-February 1995 [abstract LB6A].
-
(1995)
Second National Conference on Human Retroviruses and Related Infection
-
-
Youle, M.1
Davies, S.2
Andries, K.3
-
12
-
-
9244220064
-
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
-
Staszewski S, Miller V, Rehmet S, et al.: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996, 10:F1-F7.
-
(1996)
AIDS
, vol.10
-
-
Staszewski, S.1
Miller, V.2
Rehmet, S.3
-
13
-
-
0030317268
-
Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1-infection
-
D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1-infection. Ann Intern Med 1996, 124:1019-1030.
-
(1996)
Ann Intern Med
, vol.124
, pp. 1019-1030
-
-
D'Aquila, R.T.1
Hughes, M.D.2
Johnson, V.A.3
-
14
-
-
0027285372
-
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
-
Tisdale M, Kemp D, Parry N, Larber B: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 5653-5656
-
-
Tisdale, M.1
Kemp, D.2
Parry, N.3
Larber, B.4
-
15
-
-
0029028067
-
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
-
Larder BA, Kemp DK, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
-
(1995)
Science
, vol.269
, pp. 696-699
-
-
Larder, B.A.1
Kemp, D.K.2
Harrigan, P.R.3
-
16
-
-
0025950055
-
Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
-
St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
-
(1991)
Science
, vol.253
, pp. 1557-1559
-
-
St Clair, M.H.1
Martin, J.L.2
Tudor-Williams, G.3
-
17
-
-
0026454435
-
3′-Azido-3′-deoxythimidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
-
Larder BA: 3′-Azido-3′-deoxythimidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
-
(1992)
Antimicrob Agents Chemother
, vol.36
, pp. 2664-2669
-
-
Larder, B.A.1
-
18
-
-
0028329454
-
Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
-
Baba M, Shigeta S, Yausa S, et al.: Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994, 38:688-692.
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 688-692
-
-
Baba, M.1
Shigeta, S.2
Yausa, S.3
-
19
-
-
0027436898
-
Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleotide inhibitor, MKC-442
-
Yuasa S, Sadakata Y, Takashima H, et al.: Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleotide inhibitor, MKC-442. Mol Pharmacol 1993, 44:895-900.
-
(1993)
Mol Pharmacol
, vol.44
, pp. 895-900
-
-
Yuasa, S.1
Sadakata, Y.2
Takashima, H.3
-
20
-
-
0029944278
-
Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells
-
Okamoto M, Makino M, Yamada K, Nakade K, Yuasa S, Baba M: Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antiviral Res 1996, 31:69-77.
-
(1996)
Antiviral Res
, vol.31
, pp. 69-77
-
-
Okamoto, M.1
Makino, M.2
Yamada, K.3
Nakade, K.4
Yuasa, S.5
Baba, M.6
-
21
-
-
0029922342
-
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-) 2′,3′-dideoxy-3′-thiacytidine
-
Balzarini J, Pelemans H, Perez-Perez M-J, et al.: Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-) 2′,3′-dideoxy-3′-thiacytidine. Mol Pharmacol 1996, 49:882-890.
-
(1996)
Mol Pharmacol
, vol.49
, pp. 882-890
-
-
Balzarini, J.1
Pelemans, H.2
Perez-Perez, M.-J.3
-
22
-
-
0020261516
-
Type C virus producing cell lines derived from adult T cell leukemia
-
Miyoshi I, Taguchi H, Kubonishi I, et al.: Type C virus producing cell lines derived from adult T cell leukemia. Gann Monogr 1982, 28:219-228.
-
(1982)
Gann Monogr
, vol.28
, pp. 219-228
-
-
Miyoshi, I.1
Taguchi, H.2
Kubonishi, I.3
-
23
-
-
0029096567
-
Synthesis and antiviral activity of 6-benzil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti HIV-1 drugs
-
Tanaka H, Takashima H, Ubasawa M, et al.: Synthesis and antiviral activity of 6-benzil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti HIV-1 drugs. J Med Chem 1995, 38:2860-2865.
-
(1995)
J Med Chem
, vol.38
, pp. 2860-2865
-
-
Tanaka, H.1
Takashima, H.2
Ubasawa, M.3
-
24
-
-
0023687234
-
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
-
Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988, 20: 309-321.
-
(1988)
J Virol Methods
, vol.20
, pp. 309-321
-
-
Pauwels, R.1
Balzarini, J.2
Baba, M.3
-
25
-
-
0021118703
-
Quantitative analysis of dose-effect relationship: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalaly P: Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalaly, P.2
-
26
-
-
0028003745
-
Multiple drug effect analysis with confidence interval
-
Belen'kii MS, Schinazi RS: Multiple drug effect analysis with confidence interval. Antiviral Res 1994, 25:1-11.
-
(1994)
Antiviral Res
, vol.25
, pp. 1-11
-
-
Belen'kii, M.S.1
Schinazi, R.S.2
-
27
-
-
0028958591
-
Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442
-
Seki M, Sadakata Y, Yuasa S, Baba M: Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antiviral Chem Chemother 1995, 6:73-79.
-
(1995)
Antiviral Chem Chemother
, vol.6
, pp. 73-79
-
-
Seki, M.1
Sadakata, Y.2
Yuasa, S.3
Baba, M.4
-
28
-
-
0029024089
-
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in person treated with lamivudine (3TC)
-
Schuurman R, Nijhuis M, van-Leeuven R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in person treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
-
(1995)
J Infect Dis
, vol.171
, pp. 1411-1419
-
-
Schuurman, R.1
Nijhuis, M.2
Van-Leeuven, R.3
|